Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Not Confirmed
Not Confirmed
12-14 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Tides Asia
Not Confirmed
Contact SupplierTides Asia
Industry Trade Show
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Industry Trade Show
Not Confirmed
12-14 January, 2026
Digital content
NEWS #PharmaBuzz
18 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/18/3207494/0/en/BioNTech-Closes-Acquisition-of-CureVac-N-V-Including-Subsequent-Offering-Period-to-Strengthen-its-Unique-Position-in-the-mRNA-Field.html
12 Dec 2025
// BIOSPACE
https://www.biospace.com/fda/fda-plans-black-box-warning-for-covid-19-vaccines-report
11 Dec 2025
// INDPHARMAPOST
https://www.indianpharmapost.com/clinical-trials/biontech-and-bristol-myers-squibb-report-punchy-early-results-for-experimental-tnbc-therapy-18517
09 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/09/3202233/0/en/BioNTech-and-Bristol-Myers-Squibb-Present-First-Global-Phase-2-Data-for-PD-L1xVEGF-A-Bispecific-Antibody-Pumitamig-Showing-Encouraging-Efficacy-in-Advanced-Triple-Negative-Breast-C.html
06 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/06/3201090/0/en/BioNTech-and-OncoC4-Announce-Clinically-Meaningful-Overall-Survival-Benefit-for-Selective-Treg-Modulator-Gotistobart-in-Patients-with-Previously-Treated-Squamous-Non-Small-Cell-Lun.html
03 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/03/3198964/0/en/BioNTech-Achieves-Minimum-Condition-in-CureVac-Exchange-Offer.html
Drugs in Development
Details:
BNT162b2 Vaccine is a vaccine drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of COVID-19.
Lead Product(s): BNT162b2 Vaccine
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Vaccine
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 24, 2025
Lead Product(s) : BNT162b2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
Details : BNT162b2 Vaccine is a vaccine drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
December 24, 2025
Details:
PM8002 (Pumitamig) is a antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Glioblastoma.
Lead Product(s): Pumitamig,Bevacizumab,Temozolomide
Therapeutic Area: Oncology Brand Name: PM8002
Study Phase: Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Bristol Myers Squibb
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 22, 2025
Lead Product(s) : Pumitamig,Bevacizumab,Temozolomide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PM8002 (Pumitamig) is a antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Glioblastoma.
Product Name : PM8002
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 22, 2025
Details:
Pumitamig is a antibody drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Carcinoma, Renal Cell.
Lead Product(s): Pumitamig,Ipilimumab,Cabozantinib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Recipient: Bristol Myers Squibb
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 19, 2025
Lead Product(s) : Pumitamig,Ipilimumab,Cabozantinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pumitamig is a antibody drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Carcinoma, Renal Cell.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 19, 2025
Details:
Pumitamig is a antibody drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Carcinoma, Hepatocellular.
Lead Product(s): Pumitamig,Ipilimumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Recipient: Bristol Myers Squibb
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 18, 2025
Lead Product(s) : Pumitamig,Ipilimumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pumitamig is a antibody drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 18, 2025
Details:
Through the acquisition of CV09050101, a vaccine targeting SARS-CoV-2 S, the deal aims to advance research in glioblastoma.
Lead Product(s): CV09050101
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Vaccine
Recipient: CureVac
Deal Size: $1,250.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition December 18, 2025
Biontech Acquires CureVac N.V. to Strengthen mRNA Position
Details : Through the acquisition of CV09050101, a vaccine targeting SARS-CoV-2 S, the deal aims to advance research in glioblastoma.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
December 18, 2025
Details:
Pumitamig is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Carcinoma, Pancreatic Ductal.
Lead Product(s): Pumitamig,Oxaliplatin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Bristol Myers Squibb
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 01, 2025
Lead Product(s) : Pumitamig,Oxaliplatin,Paclitaxel,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pumitamig is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Carcinoma, Pancreatic Ductal.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 01, 2025
Details:
BNT162b2 is a Vaccine drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of COVID-19.
Lead Product(s): BNT162b2
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Vaccine
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 29, 2025
Lead Product(s) : BNT162b2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
BNT162b2-Adapted Vaccine in High-Risk Children Against Severe COVID-19
Details : BNT162b2 is a Vaccine drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
October 29, 2025
Details:
Pumitamig is an antibody candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Stomach Neoplasms.
Lead Product(s): Pumitamig,Fluorouracil,Calcium Folinate,Oxaliplatin,Nivolumab,Capecitabine
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Antibody, Unconjugated
Recipient: Bristol Myers Squibb
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 27, 2025
Lead Product(s) : Pumitamig,Fluorouracil,Calcium Folinate,Oxaliplatin,Nivolumab,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Recipient : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Pumitamig Combo vs Nivolumab in Untreated Gastric or Esophageal Cancer
Details : Pumitamig is an antibody candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Stomach Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
October 27, 2025
Details:
Pumitamig is an antibody candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Colorectal Neoplasms.
Lead Product(s): Pumitamig,Fluorouracil,Calcium Folinate,Oxaliplatin,Cetuximab,Capecitabine
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Antibody, Unconjugated
Recipient: Bristol Myers Squibb
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 27, 2025
Lead Product(s) : Pumitamig,Fluorouracil,Calcium Folinate,Oxaliplatin,Cetuximab,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Recipient : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Pumitamig Combo vs Bevacizumab in Untreated Metastatic Colorectal Cancer
Details : Pumitamig is an antibody candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Colorectal Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
October 27, 2025
Details:
BNT329 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Neoplasms.
Lead Product(s): BNT329
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody-drug Conjugate
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 22, 2025
Lead Product(s) : BNT329
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BNT329 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
September 22, 2025
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
Share 
